Transcriptional mechanisms of resistance to anti-PD-1 therapy

Clinical Cancer Research

Volumn 23, Issue 12, 2017, Pages 3168-3180

  Ascierto, Maria L ^a   Makohon Moore, Alvin ^b   Lipson, Evan J ^a   Taube, Janis M ^a   McMiller, Tracee L ^a   Berger, Alan E ^a   Fan, Jinshui ^a   Kaunitz, Genevieve J ^a   Cottrell, Tricia R ^a   Kohutek, Zachary A ^b   Favorov, Alexander ^a,c   Makarov, Vladimir ^b   Riaz, Nadeem ^b   Chan, Timothy A ^b   Cope, Leslie ^a   Hruban, Ralph H ^a   Pardoll, Drew M ^a   Taylor, Barry S ^b   Solit, David B ^b   Iacobuzio Donahue, Christine A ^b   Topalian, Suzanne L ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; PROTEIN LAMA3; UNCLASSIFIED DRUG; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLONAL VARIATION; COMPUTER MODEL; COPY NUMBER VARIATION; EVOLUTION; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MALE; METASTATIC MELANOMA; MIDDLE AGED; NEUTROPHIL; NF1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; CLONAL EVOLUTION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MELANOMA; METASTASIS; TREATMENT OUTCOME;

CLONAL EVOLUTION; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; WHOLE EXOME SEQUENCING;

EID: 85020802270     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0270     Document Type: Article

References (47)

1. Embuscado EE, Laheru D, Ricci F, Yuni KJ, Witzell SD, Seigel A, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54.
2. Gerlinger M. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-72.
3. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
4. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu BJ, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
5. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-61.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
7. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
8. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275-87.
9. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
11. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8.
12. Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 2014;30:2813-5.
13. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
14. Shen R, Seshan V. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 2016;44:e131.
15. Greenman CD, Pleasance ED, Newman S, Yang F, Fu B, Nik-Zainal S, et al. Estimation of rearrangement phylogeny for cancer genomes. Genome Res 2012;22:346-61.
16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
17. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 2016;34:155-63.
18. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
19. Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2015;47:996-1002.
20. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
21. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016;165:35-44.
22. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
23. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819-29.
24. Chen P-L, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 2016;6:827-37.
25. Felsenstein J. PHYLIP- Phylogeny Inference Package (version 3.2). Cladistics 1989;5:164-6.
26. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
27. Taube JM, Anders RA, Young GD, Xu HY, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127-37.
28. Taube JM, Young GD, McMiller TL, Chen SM, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 2015;21:3969-76.
29. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim J, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
30. Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. Bmc Bioinformatics 2006;7:85.
31. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 2007;8:R183.
32. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
33. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
34. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res 2002;30:207-10.
35. Dunning M, Lynch A, Eldridge M. IlluminaHuman WGDASLv4.db: Illumina Human WDASLv4 annotation data. R package version 1.26.0. Available from: https://www.r-project.org/.
36. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc Series A 1972;135:185-7.
37. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Hoboken (NJ): John Wiley & Sons; 2002.
38. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
39. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won HL, Liu CL, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014;74:2340-50.
40. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013;3:350-62.
41. Hugo W, Shi HB, Sun L, Piva M, Song CY, Kong XJ, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015;162:1271-85.
42. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016;532:250-4.
43. Liu C-C, Lin J-H, Hsu T-W, Hsu J-W, Chang J-W, Su K, et al. Collagen XVII/laminin-5 activates epithelial-to-mesenchymal transition and is associated with poor prognosis in lung cancer. Oncotarget 2016 Aug 11. [Epub ahead of print].
44. Seftor REB, Seftor EA, Kirschmann DA, Hendrix MJC. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 γ2 chain promigratory fragments and vaculogenic mimicry. Mol Cancer Ther 2002;1:1173-9.
45. Ryan MC, Lee K, Miyashita Y, Carter WG. Targeted disruption of the LAMA3 gene in mice reveals abnormalities in survival and late stage differentiation of epithelial cells. J Cell Biol 1999;145:1309-23.
46. Spranger S, Bao RY, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
47. Chao T, Furth EE, Vonderheide RH. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res 2016;4:968-82.